Clinical characteristics, diagnosis and prognosis of Talaromyces marneffei pneumonia in kidney transplant recipients: a retrospective study Authors: Mingda Zhong, Hedong Zhang, Han Yan, Yanjin Li, Daiwen Zhu, Shanbiao Hu, Liang Tan, Longkai Peng, Xubiao Xie, Gongbin Lan Published: 2026 ABSTRACT AbstractBackgroundTalaromyces marneffei (TM) is an opportunistic dimorphic fungus that increasingly affects immunocompromised individuals, including kidney transplant recipients. However, data on the clinical features, diagnosis, treatment, and prognosis of Talaromyces marneffei pneumonia (TMP) in this population remain limited.MethodsThis retrospective study included 8 HIV-negative kidney transplant recipients diagnosed with TMP at the Second Xiangya Hospital of Central South University between January 2015 and January 2025. Clinical data, including demographic characteristics, clinical manifestations, imaging findings, microbiological results, treatment regimens and outcomes, were collected and analyzed.ResultsThe cohort consisted of 7 males and 1 female with a mean age of 45.12 ± 9.03 years. The median time from transplantation to TMP onset was 356.5 days (IQR, 302.75–771.75). All patients presented with fever, and chest CT showed diverse pulmonary lesions, including nodules and patchy opacities. Metagenomic next-generation sequencing (mNGS) was the primary diagnostic tool, identifying TM in 7 cases (87.5%), with a mean diagnostic time of 5 ± 2.56 days, while conventional culture was positive in only 3 cases. All patients received antifungal therapy, mainly amphotericin B for induction followed by oral azoles for maintenance. Immunosuppressive regimens were adjusted during treatment. All patients achieved clinical cure without severe adverse events, and graft function remained stable.ConclusionsTMP is a rare but serious infection in kidney transplant recipients receiving long-term immunosuppression. Early diagnosis using mNGS combined with conventional culture can improve detection efficiency. Timely antifungal therapy with amphotericin B followed by azole maintenance, along with careful adjustment of immunosuppressants, is associated with favorable prognosis. Introduction Talaromyces marneffei (TM) is a thermally dimorphic fungus. First isolated from bamboo rats in Vietnam in 1956, it was initially named Penicillium marneffei. Subsequent studies demonstrated that it does not belong to the genus Penicillium but to Talaromyces, leading to its renaming as TM [1]. As a pathogen capable of causing human systemic mycosis, TM primarily invades the human body via the respiratory tract. It mainly targets the host’s mononuclear phagocyte reticuloendothelial system. Given that the respiratory system is among the earliest and most frequently affected systems, this often results in the development of Talaromyces marneffei pneumonia (TMP). If the infection progresses further, it can spread through the lymphatic or hematogenous route, leading to systemic disseminated infection and life-threatening consequences [2, 3]. Currently, kidney transplantation remains the first-line treatment modality for end-stage renal disease (ESRD). Studies have demonstrated that kidney transplant recipients exhibit significantly higher long-term survival rates compared to dialysis patients awaiting transplantation [4]. It is important to note that to prevent graft rejection, kidney transplant recipients must take immunosuppressive agents long-term; this places the body in a state of persistent immunosuppression, which in turn markedly increases the risk of various infections. Infection is not only one of the common causes of post-transplant mortality in kidney transplant recipients but may also trigger graft rejection, leading to a progressive decline in graft function and, in severe cases, graft failure [5]. Initially, TM infections predominantly occurred in human immunodeficiency virus (HIV)-positive patients, accounting for 89.9% of cases. With the advancement of organ transplantation technology, such infections have also been reported in HIV-negative populations, accounting for approximately 10.1% of cases [6]. vIn recent years, sporadic cases and small case series of TMP in non‑HIV populations have been reported, including in solid organ transplant recipients—particularly kidney transplant recipients—as well as patients with hematologic diseases and those receiving immunosuppressive therapies [7, 8]. Among these, solid organ transplant recipients, particularly kidney transplant patients, represent an emerging high-risk population due to long-term immunosuppressive regimens including calcineurin inhibitors and glucocorticoids [9]. Previous studies indicate that TM infection in kidney transplant recipients is frequently disseminated, predominantly involving the lungs followed by the liver, spleen, gastrointestinal tract, skin, and lymph nodes, and some patients develop life-threatening complications such as massive gastrointestinal bleeding or perforation [10–12]. Nevertheless, systematic data on the epidemiological characteristics, clinical manifestations, diagnostic strategies (including the application of novel techniques such as mNGS), and prognosis of TM infection in kidney transplant recipients remain limited, with no unified consensus or clinical guidelines available. Current management largely relies on small case series and expert opinion. Given the limited number of reports on TMP in kidney transplant recipients, the diagnosis and treatment strategies for this infection in this specific population remain to be improved. In this study, all kidney transplant recipients with TMP treated at our center between 2015 and 2025 were enrolled. Their clinical characteristics, diagnosis and treatment regimens, as well as the prognosis of both the recipients and grafts, were analyzed. This study aims to provide insights for the subsequent diagnosis and management of TMP in the transplant population. Materials and methods Study population From January 1, 2015 to January 1, 2025, a total of 2433 deceased donor kidney transplantations were performed in the Kidney Transplantation Department of the Second Xiangya Hospital of Central South University. A retrospective review of data was conducted on kidney transplant recipients who developed infections post-transplantation, and 8 patients diagnosed with TMP were enrolled in this study. All cases received kidneys from deceased donors (DD). Prior to transplantation, patients were tested for AIDS, and all test results were found to be negative. Data collection Collect the preoperative baseline data, post-infection clinical symptoms, laboratory test results, treatment regimens, treatment duration, prognosis and other clinical data of these infected patients. All data were obtained from China Hunan Organ Allocation and Sharing computer system (COTRS) and the electronic medical record system of the Second Xiangya Hospital of Central South University. Clinical data were collected, including demographic characteristics, underlying diseases, transplantation‑related information, clinical manifestations, laboratory test results (routine blood tests, liver and renal function, serum albumin, inflammatory markers, T lymphocyte subsets, CMV DNA load, 1,3‑β‑D‑glucan test, and galactomannan test), imaging findings, bronchoscopic results, microbiological examinations (including mNGS), treatment regimens, and follow‑up outcomes. Inclusion and exclusion criteria Kidney transplant recipients (Age ≥ 18 years) who received deceased donor renal transplantation at the Second Xiangya Hospital of Central South University from January 1, 2015 to January 1, 2025. Kidney transplant recipients (Age ≥ 18 years) who received deceased donor renal transplantation at the Second Xiangya Hospital of Central South University from January 1, 2015 to January 1, 2025. Recipients diagnosed with TMP after transplantation and receiving regular therapy. Recipients diagnosed with TMP after transplantation and receiving regular therapy. Patients with complete clinical data during treatment and follow-up duration ≥ 3 months. Patients with complete clinical data during treatment and follow-up duration ≥ 3 months. Patients with co-infections were not excluded; however, T. marneffei was considered the primary pathogen based on clinical judgment. Diagnostic criteria for TMP Diagnostic criteria for TMP were defined based on a combination of clinical, radiological and microbiological evidence: Clinical criteria: presence of fever, cough or other respiratory symptoms in kidney transplant recipients under immunosuppressive therapy; Clinical criteria: presence of fever, cough or other respiratory symptoms in kidney transplant recipients under immunosuppressive therapy; Radiological criteria: chest CT showing pulmonary abnormalities consistent with fungal infection, including nodules, patchy infiltrates, cavitary lesions or consolidation; Radiological criteria: chest CT showing pulmonary abnormalities consistent with fungal infection, including nodules, patchy infiltrates, cavitary lesions or consolidation; Microbiological criteria: (a) Isolation of TM from blood, sputum or BALF culture (gold standard); or (b) Detection of TM by mNGS in blood or BALF with supportive clinical and radiological findings. Microbiological criteria: (a) Isolation of TM from blood, sputum or BALF culture (gold standard); or (b) Detection of TM by mNGS in blood or BALF with supportive clinical and radiological findings. Fungal cultures were performed using standard microbiological procedures. Clinical specimens (blood, sputum, and BALF) were inoculated onto Sabouraud dextrose agar and incubated at both 25 °C and 37 °C to allow identification of the dimorphic characteristics of TM Cultures were monitored for up to 14 days. Identification was based on colony morphology and microscopic features. Metagenomic next-generation sequencing (mNGS) was performed on BALF or peripheral blood samples. Metagenomic next-generation sequencing (mNGS) was performed on bronchoalveolar lavage fluid (BALF) or peripheral blood samples at a certified clinical laboratory (BGI Genomics Co., Ltd., Shenzhen, China) using the BGI PMseq® pathogen detection platform. Total nucleic acids were extracted, and libraries were prepared with the MGIEasy FS DNA Library Prep Set. Sequencing was conducted on the MGISEQ-2000 platform with single-end 50 bp reads, generating at least 20 million raw reads per sample. After quality control and removal of human host sequences, the remaining reads were aligned to the BGI Pathogen Microbial Database. Talaromyces marneffei was defined as positive when at least one species-specific read was detected, combined with consistent clinical and radiological features. The turnaround time was 24–48 h. Induction and maintenance of immunosuppression Mycophenolate Mofetil (MMF) 1 g was administered orally 30 min pre-transplantation. All recipients received methylprednisolone pulse therapy (500 mg/ day, total cumulative dose 1500 mg).​ Induction therapy with anti-thymocyte globulin (ATG) was administered preoperatively to recipients of deceased donor kidneys. Maintenance therapy: A triple immunosuppressive regimen was adopted, consisting of tacrolimus, mycophenolate mofetil, and oral methylprednisolone. Postoperatively, tacrolimus dosage was dynamically adjusted according to blood concentration monitoring results. Treatment of TMP Induction therapy was administered with Amphotericin B Colloidal Dispersion(ABCD) at a dose of 3–4 mg per kilogram of body weight daily (3–4 mg/(kg·d)) for a total of 2 weeks, followed by consolidation therapy with oral itraconazole or voriconazole at 200 mg every 12 h (q12h) for an additional 10 weeks. For patients intolerant to ABCD, voriconazole was used as an alternative agent for induction therapy. Statistical methods Statistical analyses were performed using R software (version 4.5.0) and GraphPad Prism 10.0 software. Given the small sample size (n = 8) and the exploratory nature of this study, only descriptive statistics were conducted without inferential statistical testing. All continuous variables were described as mean ± standard deviation or median (interquartile range) according to distribution. No Student’s t-test or other hypothesis-testing methods were applied, and statistical significance assessments (e.g., P values) were not performed, as the sample size was insufficient to support reliable inferential analysis. Results Demographic data and clinical characteristics The demographic characteristics and basic clinical data of the study are shown in Table 1. Following kidney transplantation, these patients were administered an immunosuppressive regimen consisting of tacrolimus, mycophenolate, and methylprednisolone. Among the patients, seven were male and one was female, with an average age of 45.12 ± 9.03 (SD) years. The onset date was 356.5 days (interquartile range [IQR], 302.75–771.75) after transplantation. All patients were admitted to the hospital with fever as the initial symptom, and 2 patients were also accompanied by cough. On admission, chest CT findings showed patchy opacities in 3 cases, nodular opacities in 2 cases, patchy opacities combined with nodular opacities in 1 case, and nodular opacities with cavities in 2 cases (Fig. 1). No pleural effusion or mediastinal lymphadenopathy was detected in any patient. Table 1Characteristics of the eight patients with TMPPatientsAge(years)GenderTransplantat-ion dateOnsetdateInitial clinical symptomCT imagingDays todiagnos-isDiagnosticmethodsInduction therapyMaintenance treatmentMaintenance duration(months)Outcom-eP159Male28/6/201519/5/2023FeverPatchy opacities4BALF mNGSABCD0.15 g QdICZ 0.2 g Q12h7 monthsCureP235Male8/4/202224/3/2023Fever,CoughNodules and patchy opacities5BALF mNGSICZ0.2 g Q12hICZ 0.2 g Q12h12 monthsCureP349Female30/7/202126/4/2022FeverPatchy opacities3BALF mNGSABCD0.15 g QdICZ 0.2 g Q12h6 monthsCureP444Male2/11/20168/2/2022FeverNodular opacities5BALF mNGS,Blood cultureABCD0.15 g QdVCZ 0.2 g Q12h6 monthsCureP557Male10/7/202122/5/2022FeverPatchy opacities5BALF mNGSABCD0.15 g QdICZ 0.2 g Q12h10 monthsCureP638Male15/12/202212/1/2024FeverNodular opacities and cavities9BALF mNGS,Sputum cultureABCD0.15 g QdICZ 0.2 g Q12h6 monthsCureP738Male1/2/20232/2/2024Fever,CoughNodular opacities and cavities8BloodcultureABCD0.15 g QdVCZ 0.2 g Q12h6 monthsCureP841Male12/1/202425/7/2024FeverPatchy opacities.1BloodmNGSABCD 0.15 g QdVCZ 0.2 g Q12h7 monthsCureBALF: bronchoalveolar lavage fluid; ABCD: Amphotericin B Colloidal Dispersion; ICZ: itraconazole; VCZ: voriconazole Characteristics of the eight patients with TMP ABCD 0.15 g Qd Fever, Cough ICZ 0.2 g Q12h ABCD 0.15 g Qd BALF mNGS, Blood culture ABCD 0.15 g Qd ABCD 0.15 g Qd BALF mNGS, Sputum culture ABCD 0.15 g Qd Fever, Cough Blood culture ABCD 0.15 g Qd Blood mNGS BALF: bronchoalveolar lavage fluid; ABCD: Amphotericin B Colloidal Dispersion; ICZ: itraconazole; VCZ: voriconazole Chest CT findings in patients with TMP Two cases yielded positive results in the plasma 1,3-β-D-glucan test (G test), while one patient was positive for the galactomannan test (GM test). Admission examination results of the 8 patients revealed that 7 cases exhibited decreased counts of CD3+ T cells and CD8+ T cells, while all 8 patients showed reduced CD4+ T cell numbers. Bronchoscopic examinations in these TMP patients demonstrated varying degrees of bronchial stenosis. Some patients also presented with mucosal hyperemia, nodules, ulcers, and inflammatory exudates (Fig. 2). Flexible bronchoscopy findings in patients with TMP The average number of days from admission to confirmation of TMP was 5 ± 2.56 days. Except for patient 8 who underwent blood sampling for metagenomic next-generation sequencing (mNGS) due to high fever after admission, the remaining 7 patients underwent flexible bronchoscopy with bronchoalveolar lavage fluid (BALF) culture, and 6 patients had BALF sent for mNGS testing. TM was isolated from BALF culture in 1 patient, blood culture was positive for TM in 1 patient, and sputum culture was positive for TM in 1 patient. The baseline levels of creatinine (Cr), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in these patients were 138.55 ± 29.51 µmol/L (SD), 10.80 U/L (IQR: 9.30–15.22), and 16.89 ± 8.47 U/L (SD), respectively (Table 2). Table 2Laboratory test results of patients with TMPPatientsCr pre-(µmol/L)ALT pre-(U/L)AST pre-(U/L)G-test(pg/ml)GM-test(pg/ml)CD3+T(cells/µl)CD4+T(cells/µl)CD8+T(cells/µl)Cr post-(µmol/L)ALT post-(U/L)AST post- (U/L)P12548.716.1< 37.50.0636917518610011.420.1P2190613.8< 37.50.057962884731693.38.6P31531213.5< 37.50.1252426722712716.314.3P432324.534578.70.2541318515424721.941.1P51539.613.8267.40.034463299916612.112.4P617612.27.2< 37.50.0562933026611317.48.6P71679.512< 37.50.335372012651455935.3P816924.324.7< 37.50.5754435217217517.921.6Cr: creatinine; pre-: pre-treatment; post-: post-treatment; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CD3+T: CD3+T cells; CD4+T: CD4+T cells; CD8+T: CD8+T cells Laboratory test results of patients with TMP Cr: creatinine; pre-: pre-treatment; post-: post-treatment; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CD3+T: CD3+T cells; CD4+T: CD4+T cells; CD8+T: CD8+T cells Baseline characteristics, comorbidities, immunosuppression and CMV status Baseline characteristics, comorbidities, immunosuppressive regimens, and CMV status of the 8 kidney transplant recipients with TMP are summarized in Table 3. Among the cohort, 4 patients (50.0%) had diabetes mellitus, and 2 patients (25.0%) presented with hypoalbuminemia (serum albumin < 35 g/L). The body mass index (BMI) ranged from 16.2 to 27.2 kg/m², with 1 patient (12.5%) meeting the criteria for malnutrition (BMI < 18.5 kg/m²). All patients received maintenance immunosuppression with a triple regimen of tacrolimus (TAC), mycophenolate mofetil (MMF), and methylprednisolone (Pred), and none had a history of acute or chronic rejection before TMP diagnosis. Extrapulmonary manifestations were observed in 2 patients (25.0%), presenting as papular skin lesions, while the remaining 6 patients had no extrapulmonary involvement. Cytomegalovirus (CMV) DNA testing was performed in all patients, and all results were negative, with no concurrent CMV disease identified at the time of TMP diagnosis. In our center, flexible bronchoscopy with bronchoalveolar lavage (BAL) is a routine, standardized diagnostic procedure for kidney transplant recipients with suspected pulmonary infection. Flexible bronchoscopy was performed in 7 of the 8 patients, and the representative findings are shown in Fig. 2. The most common manifestations were diffuse mucosal hyperemia and edema of the bronchial wall, accompanied by scattered inflammatory exudate and mucus plugs in the airway lumen, observed in all 7 patients. Mucosal nodular protrusions and superficial ulcerative lesions were noted in 3 patients, as indicated by the black arrows. Bronchial stenosis due to inflammatory swelling was observed in 2 patients. All patients received standard CMV prophylaxis with oral valganciclovir 1500 mg daily for 6 months following transplantation. Because all cases of TMP occurred more than 6 months after surgery, no patient was receiving CMV prophylaxis at disease onset. Table 3Baseline comorbidities, immunosuppression, clinical statusPatientsDiabetesHypoalbuminemiaBMIMaintenance immunosuppressionRejection historyExtrapulmonary lesionsCMVP1NoNo23.1TAC + MMF + PredNoNoNegativeP2YesNo16.2TAC + MMF + PredNoPapulesNegativeP3YesNo17.5TAC + MMF + PredNoNoNegativeP4YesYes20.1TAC + MMF + PredNoNoNegativeP5NoNo20TAC + MMF + PredNoPapulesNegativeP6NoYes25.4TAC + MMF + PredNoNoNegativeP7NoNo27.2TAC + MMF + PredNoNoNegativeP8YesNo19TAC + MMF + PredNoNoNegativeTAC: tacrolimus; MMF: mycophenolate mofetil; Pred: methylprednisolone; CMV: cytomegalovirus Baseline comorbidities, immunosuppression, clinical status TAC: tacrolimus; MMF: mycophenolate mofetil; Pred: methylprednisolone; CMV: cytomegalovirus Treatments and outcomes During the anti-TMP treatment for these eight patients, the average duration of induction therapy was 10.5 days (IQR,7.75–14). Among the 8 patients, 3 patients were initially treated based on the CT imaging findings which suggested fungal infection. Based on CT imaging findings suggestive of fungal infection, empirical antifungal therapy with voriconazole was initiated. After diagnosis of TMP, 7 patients received induction therapy with amphotericin B lipid complex (ABCD), and 1 patient was given itraconazole 200 mg q12h orally for induction due to amphotericin B intolerance. While ABCD is theoretically dosed at 3–4 mg/kg/day based on body weight, the final administered dose was individually tailored for each patient according to their baseline renal function, allograft status, and drug tolerance, rather than strictly adhering to the weight-calculated dose. This individualized dosing approach was specifically designed to reduce the risk of nephrotoxicity and protect renal allograft function in this kidney transplant cohort. During maintenance treatment, all 8 patients were administered itraconazole 200 mg q12h orally. Antifungal therapy was discontinued following the resolution of fever, respiratory manifestations, and tomographic pulmonary lesions. The treatment duration ranged from 6 to 12 months, and all patients achieved clinical cure. Post-treatment, the levels of alanine aminotransferase and aspartate aminotransferase were 16.85 U/L (IQR, 11.93–18.90) and 20.25 ± 12.14 (SD) U/L, respectively. The mean creatinine level was 155.25 ± 46.06 (SD) µmol/L after treatment. During targeted therapy, maintenance therapy, and follow-up, none of the eight patients showed evidence of liver function impairment (Fig. 3A and B). Creatinine levels remained numerically stable after treatment compared with baseline (Fig. 3C), and no obvious adverse drug reactions were detected. The dose of immunosuppressants was reduced or temporarily discontinued in all patients during treatment. During treatment, radiological follow-up was performed weekly for all patients during hospitalization to assess lesion improvement, while post-discharge follow-up was individualized based on clinical symptoms and residual lesions: patients with ongoing symptoms or residual opacities received monthly chest CT at our center, and asymptomatic patients with near-complete resolution were followed at local hospitals or did not undergo routine monthly re-examination. After TMP diagnosis, all patients received individualized immunosuppressive adjustments: tacrolimus doses were reduced by 30%–50% with therapeutic drug monitoring, mycophenolate mofetil was temporarily suspended or dose-reduced, and low-dose corticosteroids were maintained to balance infection control and allograft safety. Changes in serum biochemical indicators of the patient before and after treatment (A) Changes in alanine aminotransferase (ALT) levels; (B) Changes in aspartate aminotransferase (AST) levels; (C) Changes in serum creatinine (Scr) levels Discussion Talaromyces marneffei can cause opportunistic invasive fungal infections, characterized by high recurrence and mortality rates. Due to its insidious onset and rapid progression, the diagnosis of talaromycosis is often delayed, resulting in a high mortality rate. In addition, the mortality rate among HIV-negative patients is higher than that among HIV-positive patients [7]. Nowadays, it is increasingly being reported in kidney transplant recipients. For kidney transplant recipients, long-term administration of immunosuppressants is required to prolong graft survival. However, the impairment of immune defense caused by these agents renders the host more susceptible to pneumonia, among which Talaromyces marneffei pneumonia is a relatively rare but high-risk type [13]. Study have shown that inhalation of Talaromyces marneffei spores through the respiratory tract is the most common route of infection, and the lungs are among the earliest and most frequently involved sites [14]. Therefore, understanding the clinical characteristics, diagnosis and treatment experience of Talaromyces marneffei pneumonia after kidney transplantation is of great significance for the prevention of such infections in the future. In this study, all 8 patients presented mainly with fever and respiratory symptoms, with 2 cases accompanied by cough. This is consistent with the results of previous studies, but these clinical features are also shared with other infections after kidney transplantation, such as Mycobacterium tuberculosis infection and Pneumocystis pneumonia, which can easily lead to misdiagnosis and delayed diagnosis and treatment [15]. Computed tomography (CT) has significant auxiliary diagnostic value for TMP. As the first and most frequently involved system, the respiratory system can present a variety of abnormal chest imaging findings, including patchy infiltrates, focal pulmonary consolidation, nodules, diffuse miliary lesions, and may also be complicated by pleural effusion. All 8 patients in this study showed obvious lesions on chest CT(Fig. 2). Flexible bronchoscopy may reveal pathological findings such as tracheal inflammatory changes and bronchial stenosis. Among the 7 patients who underwent bronchoscopy in the study, all presented with inflammatory manifestations including congestion, nodules, and inflammatory secretions, while 2 cases were found to have bronchial stenosis (Fig. 3). Therefore, to prevent further spread of infection and poor prognosis in patients, it is advisable to perform flexible bronchoscopy promptly once talaromycosis pneumonia is suspected, followed by further examinations of the bronchoalveolar lavage fluid (BALF). Herein, 2 patients tested positive for the G test and 1 patient for the GM test. The positive rates of both tests were relatively low, failing to provide effective and robust support for the diagnosis of Talaromyces marneffei infection. Additionally, the GM antigen exhibits cross-reactivity with Aspergillus infections, resulting in low specificity [16]. Currently, the gold standard for diagnosing Talaromyces marneffei infection remains the isolation of the pathogen in cultures of body fluid specimens. However, Hien et al. [17]. noted that such cultures may require up to 14 days to detect the pathogenic bacteria, which significantly delays diagnosis and treatment and could lead to irreversible harm or even life-threatening consequences for patients. In contrast, mNGS not only shortens the detection time to within 24 h but also exhibits higher specificity than culture methods. This enables rapid diagnosis and treatment of the disease, significantly improving the prognosis [18]. Our data showed that Talaromyces marneffei was identified in 6 patients through mNGS of bronchoalveolar lavage fluid, 1 via blood mNGS, and 1 via blood culture. The median time from admission to diagnosis was 5 ± 2.56 days, while the patient diagnosed by blood culture required 8 days from admission to confirmation. While the sample collection period of this study spans from 2015 to 2025, incident cases are predominantly concentrated in 2022 and beyond. This observation may be attributed to the integration of mNGS into routine testing for patients with post-transplant infection at our hospital in late 2021. Thus, performing mNGS on BALF or body fluids as early as possible in these patients is more conducive to their diagnosis, treatment, and long-term survival. In the eight kidney transplant recipients studied, T-lymphocyte subset analysis revealed a profound state of cellular immune deficiency, with median absolute counts of 530.5 cells/µL for CD3+, 277.5 cells/µL for CD4+, and 206.5 cells/µL for CD8 + T cells. While a CD4 + count below 200 cells/µL is the classic threshold for TMP susceptibility in HIV patients [19, 20]. Our findings underscore that transplant recipients remain highly vulnerable even at levels exceeding this marker. This suggests that long-term maintenance immunosuppression creates a ‘vulnerability window’ characterized by functional T-cell impairment. Consequently, monitoring lymphocyte profiles is vital, as any downward trend—regardless of the absolute count—necessitates heightened clinical vigilance for early TMP detection. There is no unified treatment standard for HIV-negative patients such as those who have undergone kidney transplantation. Accumulating evidence from prior research has indicated that induction therapy with amphotericin B followed by sequential itraconazole treatment serves as the first-line therapeutic strategy for HIV-positive individuals diagnosed with mucormycosis [21]. Currently, three main types of lipid formulations of amphotericin B are clinically available, namely Liposomal Amphotericin B (L-AmB), Amphotericin B Lipid Complex (ABLC), and Amphotericin B Colloidal Dispersion (ABCD). These three formulations exhibit distinct compositional differences. Specifically, L-AmB has the smallest molecular size, which allows it to evade recognition and phagocytosis by mononuclear phagocytes. Its concentrations in the liver and spleen are significantly higher than those in the kidneys and lung tissues, endowing it with the characteristic of the lowest nephrotoxicity [22]. The recommended dosage of L-AmB is 3–6 mg/kg/day. In contrast, ABLC is the largest lipid formulation, enabling it to be rapidly recognized and phagocytosed by macrophages. The clinically recommended initial dosage is 5 mg/kg/day, but both its infusion reactions and nephrotoxicity are higher than those of L-AmB [23]. After intravenous injection of ABCD, the ABCD complex remains largely intact. In addition, only a small fraction of the drug binds to circulating low-density lipoprotein (LDL), resulting in low drug concentration delivered to the kidneys [22]. Bowden et al. [24]conducted an investigation into the therapeutic efficacy of lipid-based amphotericin B preparations for invasive fungal infections. Their results revealed that while ABCD exhibited equivalent efficacy to conventional amphotericin B and offered a more favorable renal safety profile, it had a notable drawback: a significantly higher rate of infusion-related adverse events. For all TMP patients managed at our institution, ABCD was the exclusive amphotericin B formulation administered during treatment. Owing to the abbreviated inpatient treatment course, no notable infusion-associated adverse events were detected; additionally, the patients exhibited no significant deterioration in renal function post-treatment. The optimal dosage of ABCD is 3–4 mg/kg per day, whereas a dose of 8 mg/kg per day will induce severe adverse reactions involving cardiovascular impairment [25]. However, voriconazole may be considered as an alternative for patients intolerant to amphotericin B. Induction therapy with voriconazole: A loading dose of 6 mg/kg/day is administered intravenously every 12 h (q12h) on the first day. Subsequently, the dose is reduced to 4 mg/kg/day, given intravenously q12h, for 3 consecutive days. Thereafter, the regimen may be switched to oral administration of 200 mg q12h based on the patient’s renal function status [26]. In general, for TMP patients after renal transplantation, the recommended treatment regimen is as follows: ABCD at a dose of 3–4 mg/kg/day is administered intravenously for induction therapy, lasting for 2 weeks. Subsequently, the treatment is switched to oral itraconazole or voriconazole, 200 mg q12h, for maintenance therapy with a total course of 10 weeks. When voriconazole or itraconazole is used in combination with tacrolimus, strict monitoring of tacrolimus blood concentrations is required. This is because these agents can inhibit the metabolism of tacrolimus by CYP enzymes, thereby causing a significant increase in tacrolimus blood concentrations, which may lead to severe nephrotoxicity and excessive immunosuppression [12]. Caspofungin is one of the commonly used antifungal agents in kidney transplant recipients. Studies have shown that compared with amphotericin B, voriconazole, and itraconazole, caspofungin has the weakest minimum inhibitory concentration (MIC) against Talaromyces marneffei and exhibits poorer therapeutic efficacy in the treatment of Talaromyces marneffei infections [27]. This study has several limitations that should be acknowledged. First, this was a single-center retrospective study with a small sample size of only 8 patients, which may limit the statistical power and generalizability of the findings. Due to the rarity of Talaromyces marneffei pneumonia in kidney transplant recipients, assembling a larger cohort remains challenging. Second, selection bias and information bias may exist due to the retrospective design. Third, the short follow-up duration in some patients did not allow for a comprehensive assessment of long-term prognosis. Despite these limitations, to the best of our knowledge, this study reflects real-world clinical experience in the management of TMP in kidney transplant recipients from a highly endemic region. Further multicenter studies with larger sample sizes are warranted to confirm our observations and establish more standardized diagnostic and therapeutic strategies. Conclusion Talaromyces marneffei pneumonia (TMP) in kidney transplant recipients presents with non-specific clinical and radiological features, making early diagnosis challenging. Metagenomic next-generation sequencing (mNGS) improves diagnostic efficiency and enables timely targeted therapy. Amphotericin B followed by azole maintenance, along with careful adjustment of immunosuppressants, is an effective treatment strategy. With early diagnosis and appropriate management, favorable prognosis can be achieved. Acknowledgements Not applicable. Abbreviations Talaromyces marneffei Talaromyces marneffei pneumonia Metagenomic next-generation sequencing Bronchoalveolar lavage fluid Amphotericin B Colloidal Dispersion Itraconazole Voriconazole Tacrolimus Mycophenolate mofetil Methylprednisolone Cytomegalovirus Creatinine Alanine aminotransferase Aspartate aminotransferase 1,3-β-D-glucan test Galactomannan test Author contributions MZ drafted the manuscript. HZ collected and analyzed data. HY, YL, LT, SH, LP, and XX revised the manuscript. GL designed the outline of the manuscript and revised the manuscript. All authors have contributed to editing of manuscript. Mingda Zhong and Hedong Zhang contribute equally to this work and share first authorship. Funding This work is supported by Hunan Provincial Natural Science Foundation of China(2023JJ30755), Natural Science Foundation of Hunan Province (2024JJ2088), Natural Science Foundation of Hunan Province (2025JJ70074), National Natural Science Foundation of China (82370760). Data availability The raw data supporting the conclusions of this article are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Second Xiangya Hospital, Central South University (Approval No. LYF20220107, Approval Date: May 21, 2025), in accordance with the requirements of the Declaration of Helsinki. Written informed consent was obtained from all patients prior to enrollment in this study. Consent for publication Written informed consent was obtained from all individuals for the publication of any potentially identifiable images or data included in this article. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The raw data supporting the conclusions of this article are available from the corresponding author upon reasonable request.